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ackground: Hepatitis C virus or HCV is a blood borne pathogen, transmitted primarily via blood, 
body secretions and by piercing through skin (percutaneous), veins and mucosal surfaces. 
Prevalence of HCV in Pakistan is 4.5-8%. The prevalence of HCV in diabetic patients is reported 
to be 14.9% in 2016. Different studies show different prevalence of Hepatitis C in local population 
of Pakistan. This study was designed to find out the prevalence of HCV in diabetic patients of different 
age groups and gender.  
Methods: Blood samples from 259 diabetic patients were collected at Diabetes Testing and Screening 
Camp arranged by Akhuwat Health Services (AHS) at Township, Lahore. People of all age groups and 
gender were invited. Results were entered in MS Excel and analyzed on SPSS 19.  
Results: Out of 259 patients, 53% were females while 47% were males. This study shows the prevalence of 
HCV in Diabetic Patients as 8%. It was observed in diabetic patients, that females and patients from age 
group 30-40 years had high prevalence of HCV. 
Conclusion: The prevalence of Hepatitis C is high in the diabetic patients as compared to general 
population. HCV has a greater incidence in diabetic females of age group (30-40 years). 
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Introduction  
Viral hepatitis is one of the most serious pandemic 
disease. Many viruses cause hepatitis, but only few of 
them are medically important, which include HCV, 
HBV, HAV, HEV and HDV [1-3]. Number of studies 
have been done to find out the prevalence of HCV in 
Pakistan and worldwide [4, 5]. To check the variations 
in prevalence of HCV in the world, countries are 
grouped into Global Burden of Disease regions. The 
highest prevalence of HCV is reported to be in 
Central/East Asia (3.8%) and North Africa/Middle East 
regions (3.6%) [6]. HCV is an emerging major health 
issue of developing countries, including Pakistan having 
a prevalence rate of 4.5% to 8% (second highest 
prevalence rate of hepatitis C among developing 
countries). Prevalence rate of HCV is as high as 25% in 
rural and underdeveloped peri-urban areas and 40% in 
small targeted groups including drug abusers, blood 
donors, chronic liver disease patients and healthcare 
professionals. However, literature is still not conclusive 
to portrait the real image due to its limitation on 
identifying the incidence in healthy individuals [4, 7, 8].  
Recent studies show that there are 130-175 million 
people suffering from HCV out of which 350,000 die 
annually [6]. The prevalence of Hepatitis C in adult male 
of Punjab and Northern Pakistan is 4.5% and 4.0% 
respectively [9, 10]. The prevalence of Hepatitis C in 
Type 2 Diabetes Mellitus is 14.9% [11]. 
HCV is a small, enveloped single stranded RNA virus; 
two types of glycoproteins (E1 and E2) are present on its 
surface. E2 glycoprotein binds the host cell through the 
interaction with scavenger receptor class B type I (SR-
B1) and CD81 thus, target the neutralizing antibodies 
[12-14]. HCV is a blood borne pathogen, transmitted 
primarily via blood, other body secretions and by 
piercing through skin (percutaneous), veins and 
mucosal surfaces [2,3,15]. The major modes of 
transmission of HCV are; through unsafe therapeutic 
injections usage, transfusion of blood and blood 
product, shaving with unsterilized instruments by 
barbers, tattooing, transmission from mother to child, 
unsafe sexual intercourse, hemodialysis, needle-stick 
injuries among health professionals, and poor personal 
hygiene habits [16-19]. 
Re-use of contaminated needles or surgical 
instruments and improper screening of blood are the 
major risk factors [15]. Low socioeconomic status and 
poor hygienic environment are considered to be other 
major factors of such high rate of HCV infection [20]. 
Approximately, 67% population in 148 countries are 
infected with HCV through injecting drugs [21].  
Globally, reuse of unsterilized injections leads to 
approximately 2-5 million HCV infections, which lead 
to the high burden of morbidities and mortalities [22, 
23]. HCV infection has serious sequel; it can lead to 
acute and chronic hepatitis, liver diseases, liver cirrhosis 
or hepato-cellular carcinoma (HCC). Acute Hepatitis C 
clears within 6 months in 20% cases and about 80% cases 
become chronic and may progress in chronic liver 
diseases [2, 7, 24]. 
The aim of this study was to find the prevalence of 
Hepatitis C in diabetic patients in different age groups 
and gender. 
Methods 
In this cross sectional study, blood samples from 259 
diabetic patients were collected at Diabetes Testing and 
Screening Camp by Akhuwat Health Services (AHS) at 
Township, Lahore. People of all age groups and genders 
were invited. Blood was collected in evacuated tubes 
containing EDTA as an anti-coagulant. Tubes were 
centrifuged at 3400-4000 RPM for 5-10 minutes to 
collect plasma, which was stored at -2°C ice bags. 
Samples were taken to the laboratory, where HCV 
screening test was done on Immuno-chromatographic 
Kits of RapiCard™ InstaTest (Reference Number 
118773-1-44) by Diagnostic Automation/Cortez 
Diagnostic Incorporation USA. Results of the laboratory 
tests were stored in Microsoft EXCEL and analyzed 
using the Statistical Package for Social Sciences (SPSS 
19.0.verison). 
Results 
Distribution of Diabetic Patients 
In this cross-sectional study, total 259 patients were 
screened. Out of 259 patients, 53% (138/259) were 
females while 47% (121/259) were males. Frequency of 
different age groups <20, 20-30, 30-40, 40-50 and >50 
years were 7% (17/259), 13% (35/259), 25% (64/259), 
27% (69/259) and 28% (74/259) respectively (Table 1). 
Distribution of HCV Positive Diabetic Patients 
The prevalence of HCV in Diabetic Patients was 8% 
(21/259). Out of 21 HCV positive patients, 62% (13/21) 
were females while 38% (8/21) were males. The 
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proportion of HCV positive patients on their age groups 
<20, 20-30, 30-40, 40-50 and >50 years were 5% (1/21), 
24% (5/21), 33% (7/21), 14% (3/21) and 24% (5/21) 
(Table 2). 
Age Groups Frequency (n=259) Percentage 
<20 17 7% 
20-30 35 13% 
30-40 64 25% 
40-50 69 27% 
>50 74 28% 
Table 1: Different age groups of diabetic patients 
Age Groups Frequency (n=21) Percentage 
<20 1 5% 
20-30 5 24% 
30-40 7 33% 
40-50 3 14% 
>50 5 24% 
Table 2: Different age groups of HCV positive diabetic patients 
When the frequencies of age and gender of positive 
cases of HCV were checked, there were remarkable 
difference seen in both gender and age groups. 
Prevalence of HCV was significantly high in diabetic 
females (62%) as compared to diabetic male (38%). It 
was also observed in the results of this study that the 
prevalence of diabetes was high in 30-40 years age group 
i.e. 33% as shown in table 2. 
Discussion  
This study was conducted to evaluate the prevalence of 
Hepatitis C in diabetic patients of different age and 
gender. Current study estimates the prevalence of HCV 
as 8% in diabetic patients. Hussain et al, also reported a 
high prevalence (14.9%) of HCV in diabetic patients in 
2016 [11]. Findings of other studies done in Pakistan, 
UK, USA also support result of current study [25-28]. L. 
K. Chen et al in 2005 reported that a prevalence of HCV 
in diabetic patients which he reasoned might be the 
complication of diabetic therapy [29]. Result of current 
study are comparable to the studies done in Saudi Arabia 
[30] and Greek [31] and in Islamabad [32], Multan [26], 
Jhelum [33], Faisalabad [34] and Wah Cantt [35].   
Results of this study revealed that hepatitis C is highly 
prevalent in diabetic females as compared to diabetic 
males. In 2016, same results were reported in the study 
of Essa [30] and Kanwal [36]. There was no significant 
difference seen in the study of Jadoon and Ndako 
[26,37]. In contrary, Rehman et al in 2017 reported the 
highest prevalence of HCV in diabetic males [38]. 
The result showed that adults (30-40 years) have high 
frequency of HCV that was 33%. Same results were 
showed in the study of Rehman (2017) and Bostan 
(2016) [38, 39]. Ahmad et al in 2010 reported the same 
kind of results that frequency of HCV infection in 
people ≤ 40 years of age was higher than those people > 
40 years of age in Lahore [40]. Results of this study are 
in conflict with the previous studies of N. Muhammad et 
al in 2005 which showed that prevalence of HCV in 
Pakistan is more frequent in > 50 years of age [41]. 
Previous studies showed that the prevalence of HCV was 
high in 45-55 years of age groups [37, 42]. This might be 
due to an early diagnosis and increasing awareness of 
HCV in urban areas of Pakistan [16]. N. H. Saleem et al 
in 2008 showed that the modes of transmission of HCV 
were more significantly linked with age groups however 
other risk factors like blood transfusion, dental surgery 
and road accidents equally distributed in all age groups 
[43].  
The prevalence of Hepatitis C is high in the diabetic 
patients as compared to the general population of 
Lahore, Pakistan. Diabetic patients of age group (30-40) 
years have the highest risk for HCV.  In diabetic patients 
gender is also a risk factor for the Hepatitis C. Further 
studies are needed to find out the basics behind these 
high prevalence.  
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